Despite the successful efficacy of liraglutide in T2DM and obesity management, the discomfort of once-daily injection posed a barrier for patients, thereby leading to the design of a once-weekly injectable GLP-1 receptor agonist, semaglutide [29]. Here, GLP1R is linked to Obesity.